Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genital mucosa evaluation of topical product D26.255.955 under normal use conditions
RBR-437fmbzPhase 1Completed
- Sponsor
- Allergisa
- Start
- Aug 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in urogenital disease, sponsored by Allergisa. Primary endpoint: Genital mucosal safety and tolerability. Started Aug 2022; status: completed.
02
Conditions
urogenital disease
Beyond the preview
Go deeper on RBR-437fmbz.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-437fmbz.